

Title (en)

METHIMAZOLE DERIVATIVES AND TAUTOMERIC CYCLIC THIONES TO INHIBIT CELL ADHESION

Title (de)

METHIMAZOL-DERIVATE UND TAUTOMERE ZYKLISCHE THIONE ZUR HEMMUNG DER ZELLADHÄSION

Title (fr)

DERIVES DE METHIMAZOLE ET THIONES CYCLIQUES TAUTOMERES POUR INHIBER L'ADHESION CELLULAIRE

Publication

**EP 1725230 A1 20061129 (EN)**

Application

**EP 04821836 A 20040316**

Priority

US 2004007888 W 20040316

Abstract (en)

[origin: WO2005094819A1] The present invention relates to novel compounds and methods of use for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. In particular, methimazole derivatives and tautomeric cyclic thiones have the ability to inhibit the adhesion and the migration of leukocytes. In addition to being active antiinflammatories, the methimazole derivatives and tautomeric cyclic thiones and their physiologically tolerable salts, derivatives and prodrugs are generally suitable for the treatment (i.e., for the therapy and prophylaxis) of diseases that are based on the interaction between VCAM-1 and its ligands or can be influenced by an inhibition of this interaction. In particular, the methimazole derivatives and tautomeric cyclic thiones are suitable for the treatment of diseases that are caused at least partly by an undesired extent of leukocyte adhesion and/or leukocyte migration or are connected therewith, and for whose prevention, alleviation or cure the adhesion and/or migration of leukocytes should be decreased.

IPC 8 full level

**A61K 31/4164** (2006.01); **A61K 31/415** (2006.01); **A61P 1/04** (2006.01)

CPC (source: EP)

**A61K 31/415** (2013.01); **A61P 1/04** (2018.01); **A61P 1/16** (2018.01); **A61P 3/10** (2018.01); **A61P 5/14** (2018.01); **A61P 7/02** (2018.01); **A61P 7/04** (2018.01); **A61P 9/00** (2018.01); **A61P 9/10** (2018.01); **A61P 9/12** (2018.01); **A61P 9/14** (2018.01); **A61P 11/00** (2018.01); **A61P 11/02** (2018.01); **A61P 11/06** (2018.01); **A61P 11/16** (2018.01); **A61P 13/12** (2018.01); **A61P 17/00** (2018.01); **A61P 17/02** (2018.01); **A61P 17/06** (2018.01); **A61P 19/02** (2018.01); **A61P 19/10** (2018.01); **A61P 21/00** (2018.01); **A61P 25/00** (2018.01); **A61P 25/28** (2018.01); **A61P 27/02** (2018.01); **A61P 29/00** (2018.01); **A61P 31/00** (2018.01); **A61P 31/04** (2018.01); **A61P 31/06** (2018.01); **A61P 31/18** (2018.01); **A61P 33/06** (2018.01); **A61P 35/00** (2018.01); **A61P 35/04** (2018.01); **A61P 37/00** (2018.01); **A61P 37/06** (2018.01); **A61P 37/08** (2018.01); **A61P 43/00** (2018.01); **Y02A 50/30** (2018.01)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

**WO 2005094819 A1 20051013**; AU 2004317993 A1 20051013; CA 2559712 A1 20051013; EP 1725230 A1 20061129; EP 1725230 A4 20090819; JP 2007529510 A 20071025

DOCDB simple family (application)

**US 2004007888 W 20040316**; AU 2004317993 A 20040316; CA 2559712 A 20040316; EP 04821836 A 20040316; JP 2007503869 A 20040316